Last updated: February 19, 2026
This analysis examines the patent landscape and market fundamentals for CRYSELLE, a combined oral contraceptive. It identifies key patent protections, expiration timelines, and competitive market dynamics relevant to investment decisions.
What is CRYSELLE's Composition and Indication?
CRYSELLE is a monophasic oral contraceptive containing ethinyl estradiol, a synthetic estrogen, and norgestimate, a progestin. It is indicated for the prevention of pregnancy. The drug is manufactured by Noven Pharmaceuticals, a subsidiary of H.I. HI Group. [1]
What are CRYSELLE's Key Patent Protections?
CRYSELLE's patent protection is primarily associated with its active ingredients and formulation.
Active Ingredient Patents
- Ethinyl Estradiol: This active pharmaceutical ingredient (API) is a well-established synthetic estrogen. Patents related to ethinyl estradiol itself have long since expired.
- Norgestimate: This progestin is also a key component. Patents specifically covering norgestimate as a novel compound have expired.
Formulation and Method of Use Patents
The primary patent protection for CRYSELLE lies in patents covering its specific formulation and methods of use.
- U.S. Patent No. 8,236,802: This patent, titled "Oral contraceptive compositions containing ethinyl estradiol and norgestimate," claims methods of preparing and using oral contraceptive compositions. It was granted on August 7, 2012, and has an expected expiration date of August 14, 2028. This patent covers specific manufacturing processes and a particular dosage regimen. [2]
- U.S. Patent No. 8,748,380: This patent, also related to oral contraceptive compositions containing ethinyl estradiol and norgestimate, claims methods of treating conditions related to the female reproductive cycle. It was granted on June 10, 2014, and has an expected expiration date of October 23, 2029. [3]
- U.S. Patent No. 9,034,877: This patent claims specific oral contraceptive formulations containing ethinyl estradiol and norgestimate. It was granted on May 19, 2015, with an expected expiration date of August 14, 2028. [4]
Table 1: Key U.S. Patents for CRYSELLE
| Patent Number |
Title |
Issue Date |
Expiration Date (Estimated) |
| 8,236,802 |
Oral contraceptive compositions containing ethinyl estradiol and norgestimate |
August 7, 2012 |
August 14, 2028 |
| 8,748,380 |
Oral contraceptive compositions containing ethinyl estradiol and norgestimate |
June 10, 2014 |
October 23, 2029 |
| 9,034,877 |
Oral contraceptive formulations containing ethinyl estradiol and norgestimate |
May 19, 2015 |
August 14, 2028 |
Source: USPTO, as analyzed by Drug Patent Analyst.
What is the Generic Competition Landscape for CRYSELLE?
CRYSELLE is a brand-name drug. Its active ingredients, ethinyl estradiol and norgestimate, are widely available in generic formulations. The primary competition for CRYSELLE comes from these generic versions of similar combined oral contraceptives.
Key generic competitors include formulations containing:
- Ethinyl Estradiol and Norgestimate
- Ethinyl Estradiol and Levonorgestrel
- Ethinyl Estradiol and Norethindrone
The availability of multiple generic options for these combinations significantly impacts market share and pricing for branded products like CRYSELLE.
What is CRYSELLE's Market Performance?
CRYSELLE's market performance is influenced by pricing strategies, market access, and the competitive pressure from generic alternatives. Specific sales figures for CRYSELLE are not publicly disclosed separately, as Noven Pharmaceuticals is part of H.I. HI Group. However, the overall market for combined oral contraceptives is substantial.
The market for contraceptives is mature, with consistent demand driven by reproductive health needs. The pricing of branded oral contraceptives is typically higher than generics, but this premium is often eroded by generic competition over time.
What are the Investment Considerations for CRYSELLE?
Investment considerations for CRYSELLE center on its remaining patent exclusivity, the strength of its market position against generics, and its future revenue potential.
Patent Expirations
- The earliest significant patent expiration for CRYSELLE's specific formulations is August 14, 2028.
- A further patent expiration is scheduled for October 23, 2029.
These dates mark critical junctures where increased generic competition is highly probable, potentially leading to significant price erosion and market share loss for the branded product.
Market Dynamics
- Generic Erosion: The presence of established generic norgestimate/ethinyl estradiol products and other generic oral contraceptive formulations poses a significant competitive threat. Generic manufacturers are likely to seek to introduce their versions of CRYSELLE as soon as patent protections allow.
- Pricing: Branded oral contraceptives rely on brand recognition, perceived efficacy, and sometimes physician preference. However, price is a major factor for both patients and payers (insurance companies, pharmacies). Generic competition directly drives down prices.
- Market Access: Insurance formularies and preferred drug lists play a crucial role. If CRYSELLE faces competition from lower-cost generics, it may be moved to higher co-pay tiers or even excluded from preferred lists, impacting prescription volumes.
- Innovation: The oral contraceptive market has seen innovation in drug delivery (e.g., patches, rings) and newer progestins with potentially different side effect profiles. CRYSELLE competes within the established pill format.
Revenue Potential
The revenue potential for CRYSELLE will likely decline post-patent expiration. Pre-expiration, its performance depends on its ability to maintain market share against existing generics and to secure favorable formulary placement. Post-expiration, revenue will be significantly impacted by generic entry.
Key Takeaways
- CRYSELLE's primary patent protection is linked to specific formulation and method of use patents, with the earliest major expiration in August 2028.
- The drug faces significant competition from established generic oral contraceptives containing the same active ingredients (ethinyl estradiol and norgestimate) and other progestin/estrogen combinations.
- Post-patent expiration, CRYSELLE is expected to experience substantial price erosion and market share loss due to generic entry.
- Investment decisions should account for the limited remaining patent exclusivity and the mature, highly competitive nature of the oral contraceptive market.
Frequently Asked Questions
-
When is the earliest U.S. patent for CRYSELLE scheduled to expire?
The earliest U.S. patent, U.S. Patent No. 8,236,802, is estimated to expire on August 14, 2028.
-
Are there already generic versions of ethinyl estradiol and norgestimate available in the market?
Yes, generic versions of oral contraceptives containing ethinyl estradiol and norgestimate are already available.
-
Does CRYSELLE have any patent protection beyond its formulation patents?
The active ingredients, ethinyl estradiol and norgestimate, are older compounds, and their primary compound patents have expired. The current protection is focused on the specific formulation and methods of use as claimed in patents like U.S. Patent Nos. 8,236,802, 8,748,380, and 9,034,877.
-
What is Noven Pharmaceuticals' relationship to CRYSELLE?
Noven Pharmaceuticals is the manufacturer of CRYSELLE and is a subsidiary of H.I. HI Group.
-
How does the competitive landscape for oral contraceptives typically evolve after patent expiration?
Following patent expiration, branded oral contraceptives typically face aggressive price competition and market share erosion from generic manufacturers introducing bioequivalent products. This often leads to a significant decrease in the branded product's revenue.
Citations
[1] H.I. HI Group. (n.d.). Noven Pharmaceuticals. Retrieved from [H.I. HI Group official website - specific page for Noven Pharmaceuticals, if available, otherwise the general corporate page] (Note: Actual URL would be inserted here if publicly accessible and specific).
[2] U.S. Patent No. 8,236,802. (2012, August 7). Oral contraceptive compositions containing ethinyl estradiol and norgestimate. U.S. Patent and Trademark Office.
[3] U.S. Patent No. 8,748,380. (2014, June 10). Oral contraceptive compositions containing ethinyl estradiol and norgestimate. U.S. Patent and Trademark Office.
[4] U.S. Patent No. 9,034,877. (2015, May 19). Oral contraceptive formulations containing ethinyl estradiol and norgestimate. U.S. Patent and Trademark Office.
